Clinical Trial Update: C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV [Phase 3]

View source ↗

Summary

An ongoing Phase 3 trial (C-BEYOND) is evaluating the efficacy and safety of BEM/RZR versus Sofosbuvir/Velpatasvir in chronic hepatitis C virus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BEM/RZR
• Epclusa (sofosbuvir/velpatasvir)

Snippet

Sponsor: Atea Pharmaceuticals, Inc. | Conditions: HEPATITIS C VIRUS CHRONIC INFECTION | Phase 3 | Status: ACTIVE_NOT_RECRUITING